Lilly's eczema drug shows durable long-term response in late-stage study

March 27 (Reuters) - Eli Lilly said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as relief from persistent itch for up to four years in patients with the skin condition. Here are more details: * A once-monthly injection of the drug, Ebglyss - approvedin the United States in 2024 - showed durable response inpatients with moderate-to-severe